{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:08:09Z","timestamp":1792062489194,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck S.L.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11523-024-01062-z","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:02:12Z","timestamp":1716454932000},"page":"565-573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rechallenge with Anti-EGFR Treatment in RAS\/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group"],"prefix":"10.1007","volume":"19","author":[{"given":"Mercedes","family":"Salgado Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Reboredo L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Covela R\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Candamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gonz\u00e1lez-Villarroel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"S\u00e1nchez-Cousido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carral-Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Cameselle-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Varela Pose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Gallardo-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Mart\u00ednez-Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Galician Group of Research in Digestive Tumors (GITuD)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"2","key":"1062_CR1","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3390\/ijms23020852","volume":"23","author":"AL Zygulska","year":"2022","unstructured":"Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci. 2022;23(2):852. https:\/\/doi.org\/10.3390\/ijms23020852.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1062_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372\u2013401. https:\/\/doi.org\/10.3322\/caac.21728.","journal-title":"CA Cancer J Clin"},{"key":"1062_CR3","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colorectal cancer https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"issue":"7","key":"1062_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669\u201385. https:\/\/doi.org\/10.1001\/jama.2021.0106.","journal-title":"JAMA"},{"issue":"1","key":"1062_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"issue":"11","key":"1062_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cells12111458","volume":"12","author":"E Lastraioli","year":"2023","unstructured":"Lastraioli E, Bettiol A, Iorio J, Limatola E, Checcacci D, Parisi E, et al. Evaluation of RAS mutational status in liquid biopsy to monitor disease progression in metastatic colorectal cancer patients. Cells. 2023;12(11):1458. https:\/\/doi.org\/10.3390\/cells12111458.","journal-title":"Cells"},{"issue":"6","key":"1062_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41416-023-02366-z","volume":"129","author":"HL Tsai","year":"2023","unstructured":"Tsai HL, Lin CC, Sung YC, Chen SH, Chen LT, Jiang JK, et al. The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study. Br J Cancer. 2023;129(6):947\u201355. https:\/\/doi.org\/10.1038\/s41416-023-02366-z.","journal-title":"Br J Cancer"},{"key":"1062_CR8","doi-asserted-by":"publisher","first-page":"946850","DOI":"10.3389\/fonc.2022.946850","volume":"12","author":"C Cremolini","year":"2023","unstructured":"Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2023;12:946850. https:\/\/doi.org\/10.3389\/fonc.2022.946850.","journal-title":"Front Oncol"},{"issue":"8","key":"1062_CR9","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS\/BRAF wild-type circulating tumor DNA: individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Med. 2023;12(8):9392\u2013400. https:\/\/doi.org\/10.1002\/cam4.5699.","journal-title":"Cancer Med"},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2018.12.006","volume":"73","author":"G Mauri","year":"2019","unstructured":"Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41\u201353. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.006.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"1062_CR11","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/cancers13081941","volume":"13","author":"D Ciardiello","year":"2021","unstructured":"Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, et al. Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer. Cancers (Basel). 2021;13(8):1941. https:\/\/doi.org\/10.3390\/cancers13081941.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"1062_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdr623.","journal-title":"Ann Oncol"},{"issue":"6","key":"1062_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11523-020-00760-8","volume":"15","author":"LC Chong","year":"2020","unstructured":"Chong LC, Hardingham JE, Townsend AR, Piantadosi C, Rico GT, Karapetis C, et al. Rechallenge with anti-EGFR therapy in metastatic colorectal cancer (mCRC): results from South Australia mCRC registry. Target Oncol. 2020;15(6):751\u20137. https:\/\/doi.org\/10.1007\/s11523-020-00760-8.","journal-title":"Target Oncol"},{"issue":"3","key":"1062_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell\u2019Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5080.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1062_CR15","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41416-020-01042-w","volume":"123","author":"T Masuishi","year":"2020","unstructured":"Masuishi T, Tsuji A, Kotaka M, Nakamura M, Kochi M, Takagane A, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer. 2020;123(10):1490\u20135. https:\/\/doi.org\/10.1038\/s41416-020-01042-w.","journal-title":"Br J Cancer"},{"key":"1062_CR16","doi-asserted-by":"crossref","unstructured":"Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, et al. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). WCGC 2019.","DOI":"10.1093\/annonc\/mdz156.012"},{"issue":"6","key":"1062_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","volume":"16","author":"A Tsuji","year":"2021","unstructured":"Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09. Target Oncol. 2021;16(6):753\u201360. https:\/\/doi.org\/10.1007\/s11523-021-00845-y.","journal-title":"Target Oncol"},{"issue":"4_suppl","key":"1062_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1200\/JCO.2022.40.4_suppl.046","volume":"40","author":"Z Vassilev","year":"2022","unstructured":"Vassilev Z, Guo H, Lin W, Xu J, Khan N. Age-related trends in the incidence of metastatic colorectal cancer over the last 10 years: a retrospective analysis in commercially-insured population in the United States. J Clin Oncol. 2022;40(4_suppl):46\u201346.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1062_CR19","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.3390\/cancers15133509","volume":"15","author":"B Medici","year":"2023","unstructured":"Medici B, Ricc\u00f2 B, Caffari E, Zaniboni S, Salati M, Spallanzani A, et al. Early onset metastatic colorectal cancer: current insights and clinical management of a rising condition. Cancers (Basel). 2023;15(13):3509. https:\/\/doi.org\/10.3390\/cancers15133509.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"1062_CR20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01886-0.","journal-title":"Nat Med"},{"issue":"10","key":"1062_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7(10):1529\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2915.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1062_CR22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","volume":"9","author":"S Napolitano","year":"2023","unstructured":"Napolitano S, De Falco V, Martini G, Ciardiello D, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2023;9(7):966\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0655.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1062_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ijc.34632","volume":"153","author":"S Napolitano","year":"2023","unstructured":"Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer. 2023;153(8):1520\u20138. https:\/\/doi.org\/10.1002\/ijc.34632.","journal-title":"Int J Cancer"},{"issue":"4","key":"1062_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337\u201345. https:\/\/doi.org\/10.1056\/NEJMoa033025.","journal-title":"N Engl J Med"},{"issue":"4","key":"1062_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clcc.2021.07.001","volume":"20","author":"R Moretto","year":"2021","unstructured":"Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, et al. Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin Colorect Cancer. 2021;20(4):314\u20137. https:\/\/doi.org\/10.1016\/j.clcc.2021.07.001.","journal-title":"Clin Colorect Cancer"},{"issue":"3","key":"1062_CR26","doi-asserted-by":"publisher","first-page":"TPS143-TPS","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS143","volume":"39","author":"JH Strickler","year":"2021","unstructured":"Strickler JH, Ou F-S, Bekaii-Saab TS, Parseghian CM, Cercek A, Ng K, et al. PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(3):TPS143-TPS. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.TPS143.","journal-title":"J Clin Oncol"},{"key":"1062_CR27","unstructured":"Metastatic Colorectal Cancer (RAS-wildtype) after response to first-line treatment with FOLFIR plus cetuximab (AIO-KRK-0114). ClinicalTrials.gov Identifier: NCT02934529"},{"key":"1062_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940523","volume":"12","author":"S Napolitano","year":"2022","unstructured":"Napolitano S, Martini G, Ciardiello D, Di Maio M, Normanno N, Avallone A, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: a phase ii randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients. Front Oncol. 2022;12: 940523. https:\/\/doi.org\/10.3389\/fonc.2022.940523.","journal-title":"Front Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01062-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:11:06Z","timestamp":1720458666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01062-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"5 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing and editorial support were provided by Pilar L\u00f3pez, PhD, of LIDESEC, and funded by Merck S.L.U., Spain, an affiliate of Merck KGaA, Darmstadt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"<i>M<\/i><i>SF:<\/i> Advisory board\u2014Pfizer, GlaxoSmithKline, and Amgen; speaker\u2014Amgen, Sanofi, Rovi, Leo Pharma, Techdow, Eisai, MSD, AstraZeneca, Roche, Merck Serono, Servier, and Lilly; financing meetings and travel\/accommodation\u2014Servier and Merck Serono. <i>ACM:<\/i> Advisory board and\/or financing meetings and travel\/accommodation\u2014Bayer, Servier, Merck, and Amgen. <i>PGV:<\/i> financing meetings and travel\/accommodation\u2014Amgen. <i>MEGM:<\/i> financing meetings and travel\/accommodation\u2014Amgen. <i>BGS:<\/i> Advisory board and\/or financing meetings and travel\/accommodation\u2014Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead Sciences, Merck, Sanofi, and Servier. <i>NML:<\/i> Consultant or advisory role\u2014AAA (Novartis), Amgen, Bayer, BMS, Esteve, Ipsen, Leo Pharma, Lilly, Merck, MSD, Pierre Fabre, and Servier; travel grant\u2014Amgen, Advanz, Ipsen, Lilly, and Servier. <i>MRL<\/i>, <i>MCR<\/i>, <i>SCF<\/i>, <i>LFSC<\/i>, <i>SCG,<\/i> and <i>VVP<\/i> report they have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved on 31 March 2022 by the Galician Ethics Committee of Research with Medicines (CEIm-G), prior to starting data collection. This observational study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki, the International Conference on Harmonisation\u2019s Guidelines for Good Clinical Practice, the Guidelines for Good Pharmacoepidemiology Practices, and applicable legislation on noninterventional studies and\/or observational studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all living individual participants. Deceased patients were included in the study, except those who expressed their objection to the use of their data for research or to participation in research studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors contributed to the study conception and design, material preparation, and data collection and analysis. All authors commented on previous versions of the manuscript and contributed to the writing of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data that support the findings of this study are not openly available; they are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}